Skip to content

Link Between Plasma Citrulline and Lipopolysaccharide Concentrations in the Critically Ill

Link Between Plasma Citrulline and Lipopolysaccharide Concentrations in the Critically Ill

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02902276
Acronym
CITRANS
Enrollment
120
Registered
2016-09-15
Start date
2016-07-31
Completion date
2017-02-28
Last updated
2016-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill

Keywords

plasma citrulline, lipopolysaccharide, critically ill, Hospitalization in an Intensive Care Unit

Brief summary

In critically ill patients, the small bowel permeability is increased, leading to bacterial translocation, and systemic inflammatory response syndrome. Plasma citrulline is a validated biomarker of functional enterocyte mass. Lipopolysaccharide (LPS) is a part of Gram negative bacteria, and plasma LPS concentration is a biomarker of bacterial translocation. The link between plasma citrulline and LPS in the critically ill is unknown. Investigators hypothesize that patients presenting with low plasma citrulline concentration, with presumed altered small bowel function, would have an increased phenomenon of bacterial translocation, and increased plasma LPS concentration. Investigators aimed to evaluate the link between plasma citrulline and LPS concentrations in critically ill patients at the time of ICU admission.

Interventions

Two blood samples will be taken at ICU admission

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Critically ill patients requiring ICU admission for at least 48 hours * Adults

Exclusion criteria

* Chronic small bowel disease * Chronic renal failure (clearance of creatinine \< 50 mL/min) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Plasma citrulline concentrationUp to 12 hours after admission in the unitbiological assay
plasma lipopolysaccharide concentrationUp to 12 hours after admission in the unitbiological assay

Countries

France

Contacts

Primary ContactGaël Piton, MD, PhD
gpiton@chu-besancon.fr0033381668224

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026